MARKET

ARDX

ARDX

Ardelyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6578
-0.0362
-5.22%
After Hours: 0.6900 +0.0322 +4.90% 19:55 05/18 EDT
OPEN
0.6832
PREV CLOSE
0.6940
HIGH
0.6999
LOW
0.6552
VOLUME
1.65M
TURNOVER
103.33K
52 WEEK HIGH
8.25
52 WEEK LOW
0.5770
MARKET CAP
95.12M
P/E (TTM)
-0.4703
1D
5D
1M
3M
1Y
5Y
BRIEF-Ardelyx Announces Additional Data Supporting The Efficacy And Safety Of First-In-Class Ibsrela For Adults With IBS-C
reuters.com · 1d ago
Ardelyx Announces Additional Data Co Says Supports Efficacy And Safety Of First-In-Class IBSRELA (tenapanor) For Adults With IBS-C, To Be Presented At DDW 2022
Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022 WALTHAM, Mass., May 17, 2022 /PRNewswire/ --
Benzinga · 1d ago
Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting the effic...
PR Newswire · 1d ago
Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on May 9, 2022, the compensation com...
PR Newswire · 2d ago
Accelerate Diagnostics rises 7% on commercialization of Accelerate Arc system for use in blood culture test
Accelerate Diagnostics (NASDAQ:ARDX) is trading 7.2% higher after the company announced on Monday the commercialization of its new Accelerate Arc Module and BC (blood culture) kit for accurate microbial identification for positive blood cultures.
Seekingalpha · 2d ago
Catalyst watch: Rivian lockup expires, Western Digital event and inflation prints
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 05/06 19:00
Ardelyx falls as downgraded to Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen downgraded Ardelyx (ARDX -6.4%) to Neutral from Overweight with a $1 price target, down from $7. Chen sees increasing execution and competitive risks for the
Seekingalpha · 05/06 17:26
Cantor Fitzgerald Cuts Ardelyx Price Target After Q1 Results; Shares Fall
MT Newswires · 05/06 14:18
More
No Data
Learn about the latest financial forecast of ARDX. Analyze the recent business situations of Ardelyx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
12.50%Buy
37.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ARDX stock price target is 6.29 with a high estimate of 15.00 and a low estimate of 1.000.
High15.00
Average6.29
Low1.000
Current 0.6578
EPS
Actual
Estimate
-0.36-0.27-0.18-0.09
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 148
Institutional Holdings: 50.54M
% Owned: 34.95%
Shares Outstanding: 144.60M
TypeInstitutionsShares
Increased
30
6.30M
New
25
10.06M
Decreased
29
5.14M
Sold Out
33
18.03M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.24%
Pharmaceuticals & Medical Research
-2.06%
Key Executives
Non-Executive Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Michael Raab
Chief Financial Officer/Chief Accounting Officer
Justin Renz
Senior Vice President - Finance/Chief Accounting Officer
Robert Felsch
Chief Administrative Officer
Elizabeth Grammer
Chief Scientific Officer
Jeffrey Jacobs
Other
Robert Blanks
Other
Susan Rodriguez
Other
David Rosenbaum
Independent Director
Robert Bazemore
Independent Director
William Bertrand
Independent Director
Muna Bhanji
Independent Director
Geoffrey Block
Independent Director
Onaiza Cadoret - Manier
Independent Director
Jan Lundberg
Independent Director
Richard Rodgers
No Data
No Data
About ARDX
Ardelyx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines to improve treatment for people with kidney and cardiorenal diseases. The Company's product pipeline includes Tenapanor, IBSRELA, RDX013 Program, and RDX020 Program. The Tenapanor is a medicine for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor for the control of serum phosphorus has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). RDX013 Program is a small molecule potassium secretagogue program for the potential treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis. It has a discovery program targeting the inhibition of intestinal bicarbonate exchange for the treatment of metabolic acidosis.

Webull offers kinds of Ardelyx Inc stock information, including NASDAQ:ARDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform.